NIBEC CO., LTD.
Financials
Valuation Metrics
NIBEC CO., LTD.'s Market Cap is ₩1705B. At end of 2025 it was ₩4269B. Ranked #915 of 2,436 in KR market (top 38%), #433 of 1,649 on KOSDAQ (top 26%), #103 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 44%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 170.52B KRW | KR#915/2,436 Sec#103/234 |
| Revenue | 32.34B KRW | KR#2,000/2,436 Sec#136/234 |
| Net Income | 7.30B KRW | KR#999/2,436 Sec#65/234 |
| Total Assets | 63.61B KRW | KR#2,050/2,436 Sec#175/234 |
| Net Assets | 47.02B KRW | KR#1,918/2,436 Sec#166/234 |
| Employees | 96 | KR#1,657/2,436 Sec#128/234 |
| Value | ||
| P/E | 23.37x | KR#1,166/2,436 Sec#69/234 |
| P/B | 3.63x | KR#2,173/2,436 Sec#175/234 |
| P/S | 5.27x | KR#2,153/2,436 Sec#142/234 |
| EV/EBITDA | 25.89x | KR#1,137/2,436 Sec#70/234 |
| FCF Yield | 2.54% | KR#1,026/2,436 Sec#69/234 |
| Profitability | ||
| ROE | 15.52% | KR#217/2,436 Sec#15/234 |
| ROA | 11.47% | KR#147/2,436 Sec#14/234 |
| Op. Margin | 19.74% | KR#156/2,436 Sec#17/234 |
| Revenue Growth | -6.69% | KR#1,761/2,436 Sec#163/234 |
| Financial Health | ||
| Debt Ratio | 135.28% | KR#948/2,436 Sec#112/234 |
| Total Debt | 17.41B KRW | KR#1,408/2,436 Sec#118/234 |
| FCF | 4.33B KRW | KR#938/2,436 Sec#66/234 |
| Cash | 22.60B KRW | KR#1,166/2,436 Sec#84/234 |
| Current Ratio | 3.35x | KR#542/2,436 Sec#82/234 |
| Net Debt/EBITDA | -0.81x | KR#511/2,436 Sec#29/234 |
| Performance | ||
| 1Y Return | -34.07% | KR#1,675/2,436 Sec#146/234 |
| 1M Return | -11.71% | KR#1,858/2,436 Sec#187/234 |
| From 52W High | -72.38% | KR#2,217/2,436 Sec#206/234 |
| 1Y MDD | -76.67% | KR#2,209/2,436 Sec#202/234 |
| Trading | ||
| Volume | 23,797 shares | KR#1,772/2,436 Sec#178/234 |
| Foreign Own. | 3.85% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 646 KRW | KR#812/2,436 Sec#60/234 |
| BPS | 4,136 KRW | KR#1,594/2,436 Sec#123/234 |
Company Info
NIBEC, established in 2004, was founded to commercialize research from the Seoul National University College of Dentistry's Intelligent Bio-Interface Engineering Research Center. The company develops peptide-based drugs, convergence biomaterials, and protein engineering technology-based drugs, leveraging peptide-based drug delivery systems and biomaterial technology for tissue regeneration. Its dental bio-regeneration materials are sold globally through Straumann and Nobel Biocare, having received NMPA sales approval in China in 2020. NIBEC is headquartered in Jincheon-gun, Chungcheongbuk-do.